[vc_row][vc_column][vc_column_text css_animation=”fadeInDown”]

MannKind Corporation (NASDAQ:MNKD) Rating Reiterated by HC Wainwright

[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column width=”1/2″][vc_column_text css_animation=”fadeInLeft”]MannKind Corporation (NASDAQ:MNKD)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued to clients and investors on Tuesday, October 24th.

Other equities analysts have also issued research reports about the stock. Maxim Group restated a “buy” rating on shares of MannKind Corporation in a report on Friday, September 1st. ValuEngine lowered shares of MannKind Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. Finally, Zacks Investment Research upgraded shares of MannKind Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company’s stock. MannKind Corporation has an average rating of “Hold” and an average target price of $0.92.

MannKind Corporation (NASDAQ MNKD) traded up $0.03 during mid-day trading on Tuesday, reaching $3.26. 5,324,860 shares of the company’s stock traded hands, compared to its average volume of 13,918,669. The stock has a market cap of $374.49, a PE ratio of 6.04 and a beta of 3.10. MannKind Corporation has a 12-month low of $0.67 and a 12-month high of $6.96. The company has a debt-to-equity ratio of -0.48, a current ratio of 0.59 and a quick ratio of 0.56.[/vc_column_text][/vc_column][vc_column width=”1/2″][vc_raw_html]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[/vc_raw_html][vc_raw_html]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[/vc_raw_html][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css_animation=”fadeIn”]MannKind Corporation (NASDAQ:MNKD) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.10). The company had revenue of $2.16 million during the quarter, compared to analyst estimates of $2.75 million. MannKind Corporation had a net margin of 71.60% and a negative return on equity of 24.93%. During the same quarter last year, the business earned $0.08 EPS. equities analysts anticipate that MannKind Corporation will post -1.02 earnings per share for the current year.

In related news, Director Kent Kresa bought 166,600 shares of the company’s stock in a transaction dated Friday, October 13th. The stock was bought at an average price of $6.00 per share, with a total value of $999,600.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.40% of the stock is currently owned by insiders.

Several large investors have recently made changes to their positions in the stock. Harel Insurance Investments & Financial Services Ltd. grew its position in shares of MannKind Corporation by 20.1% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 588,520 shares of the biopharmaceutical company’s stock valued at $830,000 after buying an additional 98,520 shares during the last quarter. Dupont Capital Management Corp acquired a new position in MannKind Corporation during the 3rd quarter valued at about $219,000. KCG Holdings Inc. boosted its stake in MannKind Corporation by 268.0% during the 1st quarter. KCG Holdings Inc. now owns 147,952 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 107,752 shares during the period. LMR Partners LLP acquired a new position in MannKind Corporation during the 2nd quarter valued at about $352,000. Finally, Balyasny Asset Management LLC acquired a new position in MannKind Corporation during the 2nd quarter valued at about $568,000. 14.59% of the stock is owned by institutional investors and hedge funds.

About MannKind Corporation

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.[/vc_column_text][vc_raw_html]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[/vc_raw_html][/vc_column][/vc_row]